Cargando…
Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome
The proteasome is a validated target in drug discovery for diseases associated with unusual proteasomal activity. Here we report that two diphenyldihaloketones, CLEFMA and EF24, inhibit the peptidase activity of the 26S proteasome. The objective of this study was to investigate interaction of these...
Autores principales: | Rao, Geeta, Nkepang, Gregory, Xu, Jian, Yari, Hooman, Houson, Hailey, Teng, Chengwen, Awasthi, Vibhudutta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153970/ https://www.ncbi.nlm.nih.gov/pubmed/30280096 http://dx.doi.org/10.3389/fchem.2018.00392 |
Ejemplares similares
-
Stability study on an anti-cancer drug 4-(3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid (CLEFMA) using a stability-indicating HPLC method
por: Raghuvanshi, Dhawal, et al.
Publicado: (2017) -
Ubiquitin-Proteasome System in Neurodegenerative Disorders
por: Rao, Geeta, et al.
Publicado: (2015) -
Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer
por: Yari, Hooman, et al.
Publicado: (2019) -
Drug‐induced cardiomyopathy: Characterization of a rat model by [(18)F]FDG/PET and [(99m)Tc]MIBI/SPECT
por: Houson, Hailey, et al.
Publicado: (2020) -
Anti-Cancer and Ototoxicity Characteristics of the Curcuminoids, CLEFMA and EF24, in Combination with Cisplatin
por: Monroe, Jerry D., et al.
Publicado: (2019)